Search results with tag "Ozempic"
![[Product Monograph Template - Schedule D] - novonordisk.ca](/cache/preview/d/4/6/e/b/1/2/5/thumb-d46eb12554b4ea3c3e73eb4fb39cc2d4.jpg)
[Product Monograph Template - Schedule D] - novonordisk.ca
www.novonordisk.caOZEMPIC® (semaglutide injection) Product Monograph Page 1 of 59 . PRODUCT MONOGRAPH . INCLUDING PATIENT MEDICATION INFORMATION . OZEMPIC ® semaglutide injection . 2 mg/pen (1.34 mg/mL) 4 mg/pen (1.34 mg/mL) Pre-filled pen delivering doses of 0.25 mg or 0.5 mg
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.novo-pi.comOZEMPIC ® semaglutide) injection, for sucutaneous use 2 FULL PRESCRIBING INFORMATION WARNING: RISK OF THYROID C−CELL TUMORS • persistent hoarseness).In rodents, semaglutide causes dose-dependent and treatment-duration-
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.novo-pi.com7 8. mmr c nt eI i pi aHt pae 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Overview of Clinical Studies 14.2 Monotherapy Use of OZEMPIC® in Patients with